You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Innovative Tools for Three Dimensional Traction Force Microscopy of Single Cells

    SBC: SIMMETRIX INC.            Topic: 102

    Project Summary Tractions exerted by individual cells on their surroundings play a critical role in mechanical events in biology such as tissue contraction folding cell shape changes or cell movements and in many basic cellular functions such as biochemical signaling proliferation and differentiation These processes are in turn implicated in the progression of diseases like cancer atherosc ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease Using Skin Elasticity as a Biomarker

    SBC: Microelastic Ultrasound Systems, Inc.            Topic: 102

    Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease using Skin Elasticity as a Biomarker ABSTRACT Sclerotic chronic graft versus host disease cGVHD develops in of allogenic Human Stem Cell Transplant HCT recipients and is associated with significant morbidity and mortality GVHD is treated with immunosuppression which puts patients at severe risk of infection ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. AML MutationCounter a tool to detect residual and recurrent leukemia

    SBC: Asystbio Laboratories, LLC            Topic: 102

    Abstract AsystBio LLC proposes to market a molecular tool kit called AML MutationCounter to count somatic mutations in genes that contribute to the development of acute myeloid leukemia AML We have developed a set of reagents and computer programs for application of next generation sequencing to count AML gene mutations The tool kit is versatile and can be used with either of the two major DNA ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Creation of animal models of mitochondrial DNA disease for translational research applications

    SBC: Enzerna Biosciences LLC            Topic: 400

    Mitochondria are the principal generators of cellular ATP by oxidative phosphorylation which links electron transport via Complexes I through IV to production of ATP via ATP synthase Over pathogenic human mitochondrial DNA mtDNA mutations associated with diseases ranging from cardiomyopathy to juvenile blindness have been identified Collectively millions are affected by mtDNA disease fo ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a New Carbohydrate based Anticoagulant Drug

    SBC: Glycan Therapeutics LLC            Topic: NHLBI

    Low molecular weight heparins LMWHs a commonly used anticoagulant drug in the hospitals are carbohydrate based molecules Heparin is isolated from porcine intestine through a long and unreliable supply chain LMWH is a depolymerized product of heparin A worldwide distribution of contaminated heparin in impacting the purity and safety of LMWHs was associated with deaths in the US Th ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Hernia Mesh to Improve Anchor Point Fixation and Prevent Hernia Formation

    SBC: Deep Blue Medical Advances, Inc.            Topic: 300

    Abstract Two million laparotomies are performed annually in the U S with ventral hernia being a frequent complication in of patients The average cost patient for each hernia operation in the U S in was $ which amounts to $ billion annually The ten year ventral hernia recurrence rate is There are $ B in hernia meshes sold annually in the United States With ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Point of Care Imaging for Cardiovascular Monitoring Light Energy Tissue Interactions

    SBC: RFPi, Inc.            Topic: NHLBI

    A research team of clinical medicine optical physics mechanical and electrical engineering disciplines at ECU has invented a new biomedical imaging technology Multi Spectral Physiologic Visualization MSPV MSPV is a proprietary laser illuminated hardware software imaging system that is non contact cm imaging distance non invasive no dyes or injections non ionizing no X ray CT an ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Structure based optimization of a novel pharmacological chaperone therapy for MPSIIIC

    SBC: Phoenix Nest Inc.            Topic: NICHD

    PROJECT SUMMARY Lysosomal storage diseases LSD are rare inherited metabolic disorders caused by defects in the cellular catabolic system Mucopolysaccharidosis Type IIIC MPS IIIC or Sanfilippo disease type C is one such LSD that is caused by deficiency of the enzyme heparan sulfate acetyl CoA glucosaminide N acetyltransferase HGSNAT essential for degradation of heparan sulfate a repeati ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government